RxDoctor Payments Data

John Brandt, MD

Clinical Cardiac Electrophysiology · Asheville, NCNPI 1730472382

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 31.2% of the total.

$38,955in general payments, 2019–2025

Across 378 payments — averaging $103.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Boston Scientific$11K
  • Medtronic$6K
  • Biotronik Inc.$3K
  • Altathera Pharmaceuticals LLC$2K
  • Biosense Webster, Inc.$1K
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$5,50014%
  • Speaking & faculty fees$2,0005%
  • Grants$5,00013%
  • Travel & lodging$7,93120%
  • Food & beverage$18,02946%
  • Education$4941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,955 in reported general payments places this provider in the 60th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$348,525
Medicare patients
734
Services billed
4,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$323,947
XareltoRivaroxaban167$163,349
MultaqDronedarone Hcl41$55,590
EntrestoSacubitril/Valsartan41$31,089
JardianceEmpagliflozin19$21,521
Dofetilide97$17,027
Metoprolol Succinate169$2,214
Amiodarone Hcl201$2,188
Mexiletine Hcl35$1,819
SotalolSotalol Hcl66$1,754
Flecainide Acetate48$1,278
Valsartan36$869
Mupirocin81$652
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$650
Spironolactone63$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$299$323,947290 claims
Johnson & JohnsonXarelto$127$163,349167 claims
Boehringer IngelheimJardiance$331$21,52119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →